Nonphospholipid vesicles of Carboplatin for lung targeting.
Carboplatin (CPt) was incorporated into nonphospholipid vesicles (NPLV) by the method of membrane dispersion and its content determined spectrophotometrically. The particle size was between 2.0-10.0 microm with a mean value of 3.26 microm and a span of 0.55; and the drug content was 3.965 mg/ml. Dynamic dialysis was used for in vitro release of CPt and the results indicated that the drug release t(1/2) was increased eight times, compared with the original drug. These parameters had little change after lyophilization. When tested with mice, the body distribution parameters showed obviously lung targeting characteristics. The S-180 lung neoplasm models were established by intravenous cancer cells in mice and the number of pulmonary nodules examined for evaluation of the therapeutic efficacy. Antitumor effect was increased and differed significantly (p <.05) compared with the original drug of the same dose.
Lu
B
B
West China School of Pharmacy, Sichuan University, Chengdu, China. lubin@wcums.edu.cn
Zhang
J Q
JQ
Yang
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D004339:Drug Compounding; D016503:Drug Delivery Systems; D007275:Injections, Intravenous; D008081:Liposomes; D008168:Lung / Q000098:blood supply* / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D010316:Particle Size; D013501:Surface-Active Agents; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008081:Liposomes; D013501:Surface-Active Agents; D016190:Carboplatin